Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.

Tallantyre, Emma C., Scurr, Martin J., Vickaryous, Nicola, Richards, Aidan, Anderson, Valerie, Baker, David, Chance, Randy, Evangelou, Nikos, George, Katila, Giovannoni, Gavin, Harding, Katharine E., Hibbert, Aimee, Ingram, Gillian, Jolles, Stephen, Jones, Meleri, Kang, Angray S., Loveless, Samantha, Moat, Stuart J., Robertson, Neil P., Rios, Francesca, Schmierer, Klaus, Willis, Mark, Godkin, Andrew and Dobson, Ruth 2022. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis. Multiple Sclerosis and Related Disorders 64 , 103937. 10.1016/j.msard.2022.103937

[thumbnail of PIIS2211034822004485.pdf] PDF - Published Version
Available under License Creative Commons Attribution.

Download (770kB)

Abstract

Background People with MS treated with anti-CD20 therapies and fingolimod often have attenuated responses to initial COVID-19 vaccination. However, uncertainties remain about the benefit of a 3rd (booster) COVID-19 vaccine in this group. Methods PwMS without a detectable IgG response following COVID-19 vaccines 1&2 were invited to participate. Participants provided a dried blood spot +/- venous blood sample 2–12 weeks following COVID-19 vaccine 3. Humoral and T cell responses to SARS-CoV-2 spike protein and nucleocapsid antigen were measured. Results Of 81 participants, 79 provided a dried blood spot sample, of whom 38 also provided a whole blood sample; 2 provided only whole blood. Anti-SARS-CoV-2-spike IgG seroconversion post-COVID-19 vaccine 3 occurred in 26/79 (33%) participants; 26/40 (65%) had positive T-cell responses. Overall, 31/40 (78%) demonstrated either humoral or cellular immune response post-COVID-19 vaccine 3. There was no association between laboratory evidence of prior COVID-19 and seroconversion following vaccine 3. Conclusions Approximately one third of pwMS who were seronegative after initial COVID-19 vaccination seroconverted after booster (third) vaccination, supporting the use of boosters in this group. Almost 8 out of 10 had a measurable immune response following 3rd COVID-19 vaccine.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: Elsevier
ISSN: 2211-0348
Funders: N/A
Date of First Compliant Deposit: 14 June 2022
Date of Acceptance: 3 June 2022
Last Modified: 14 Jun 2022 15:31
URI: https://orca.cardiff.ac.uk/id/eprint/150371

Citation Data

Cited 1 time in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics